Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis by Simone MC Spoorenberg et al.
RESEARCH ARTICLE Open Access
Microbial aetiology, outcomes, and costs of
hospitalisation for community-acquired
pneumonia; an observational analysis
Simone MC Spoorenberg1*, Willem Jan W Bos1, Rik Heijligenberg2, Paul GP Voorn3, Jan C Grutters4,5, Ger T Rijkers3,6
and Ewoudt MW van de Garde7,8
Abstract
Background: The aim of this study was to investigate the clinical outcome and especially costs of hospitalisation
for community-acquired pneumonia (CAP) in relation to microbial aetiology. This knowledge is indispensable to
estimate cost-effectiveness of new strategies aiming to prevent and/or improve clinical outcome of CAP.
Methods: We performed our observational analysis in a cohort of 505 patients hospitalised with confirmed CAP
between 2004 and 2010. Hospital administrative databases were extracted for all resource utilisation on a patient
level. Resource items were grouped in seven categories: general ward nursing, nursing on ICU, clinical chemistry
laboratory tests, microbiology exams, radiology exams, medication drugs, and other.linear regression analyses were
conducted to identify variables predicting costs of hospitalisation for CAP.
Results: Streptococcus pneumoniae was the most identified causative pathogen (25%), followed by Coxiella burnetii
(6%) and Haemophilus influenzae (5%). Overall median length of hospital stay was 8.5 days, in-hospital mortality rate
was 4.8%.
Total median hospital costs per patient were €3,899 (IQR 2,911-5,684). General ward nursing costs represented the
largest share (57%), followed by nursing on the intensive care unit (16%) and diagnostic microbiological tests (9%).
In multivariate regression analysis, class IV-V Pneumonia Severity Index (indicative for severe disease), Staphylococcus
aureus, or Streptococcus pneumonia as causative pathogen, were independent cost driving factors. Coxiella burnetii
was a cost-limiting factor.
Conclusions: Median costs of hospitalisation for CAP are almost €4,000 per patient. Nursing costs are the main
cause of these costs.. Apart from prevention, low-cost interventions aimed at reducing length of hospital stay
therefore will most likely be cost-effective.
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Background
Community-acquired pneumonia (CAP) is one of the most
common infectious diseases worldwide; in the developed
world, CAP, combined with influenza, is the primary cause
of death due to infection [1]. Incidence of CAP is high
in young children, then decreases and in adults, again
increases with age; consequently, CAP carries a high
burden, in particular in the elderly [2,3]. As 20-40% of
all CAP episodes in the elderly are treated in-hospital [4],
hospital admissions for pneumonia result in considerable
health care costs [2,5]. In 1997, these costs were estimated
to be €115 million in Spain [6] and almost £400 million in
the United Kingdom [7]. With the post Second World
War generation approaching senescence and the rise of
life expectancy in general, the number of hospital admis-
sions for pneumonia and associated health care costs will
continue to rise [8].
Many studies have been conducted to assess the effect of
interventions with the aim of reducing the risk and improv-
ing the outcome of CAP. For instance, the introduction
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of vaccination against Influenza has reduced severity and
mortality of secondary pneumonia [9], adjunctive therapies
such as corticosteroids have been shown to reduce length
of hospital stay [10] and some studies showed lowering
of incidence and mortality of pneumococcal pneumonia
in nursing home residents through use of pneumococcal
vaccines [11] although others found no protective effect
[12-14]. In order to determine overall cost-effectiveness
of such interventions, knowledge of the association be-
tween microbial aetiology, outcomes, and costs of CAP
is indispensable.
The objectives of the present study were to analyse
microbial aetiology and clinical outcomes of a large cohort
of patients hospitalised for CAP, to determine individual
hospital resource utilization, to quantify total costs of hos-
pitalisation for CAP and to explore possible associations
between microbial aetiology and the corrsponding costs.
Methods
Patients
Patients with CAP above 18 years of age admitted to the
St. Antonius Hospital in Nieuwegein or the Gelderse
Vallei Hospital in Ede (both teaching hospitals in the
Netherlands), between October 2004 and August 2006
(n = 201), and between November 2007 and September
2010 (n = 304), who participated in two consecutive
clinical studies were enrolled. The first study was a pro-
spective cohort study on clinical characteristics and
polymorphisms in innate immunity genes in patients
with CAP; the second study was a placebo controlled
double blind randomized clinical trial evaluating dexa-
methasone as adjunctive therapy (NCT00471640). In
both studies, the same clinical inclusion criteria were
used and patient characteristics of the patients studied
resembled data from another large CAP cohort (over
20,000 patients admitted to hospital for pneumonia)
from the same time period [15]. CAP was defined as a
new pulmonary infiltrate on chest radiograph, in com-
bination with at least two of the following criteria:
cough, sputum production, temperature above 38°C or
below 35°C, auscultatory findings consistent with pneu-
monia, C-reactive protein concentration of more than
15 mg/L, and white blood cell count of above 10 × 109
cells/L or below 4 × 109 cells/L, or >10% of rods in
leukocyte differentiation. Patients who were immunocom-
promised, had been directly admitted to the intensive care
unit (ICU), or who had received immunosuppressive ther-
apy (including the use of >20 mg prednisone equivalent
per day for >3 days) were excluded. More detailed inclu-
sion and exclusion criteria are described elsewhere
[10,16]. Comorbidities were recorded of each patient and
pneumonia severity index (PSI) score was calculated on
admission. The present study has been approved by the
Medical Ethical Committees of the St. Antonius Hospital
(Nieuwegein) and the Gelderse Vallei Hospital (Ede), both
in The Netherlands.
Microbial aetiology
At least two sets of separate blood and sputum samples of
each patient were Gram stained and cultured. Streptococcus
(S.) pneumoniae cultured from either sputum or blood was
serotyped by the Quellung reaction. Moreover, sputum
samples were analysed with TaqMan real-time polymerase
chain reactions (PCRs) in order to detect DNA of Myco-
plasma (M.) pneumoniae, Legionella (L.) pneumophila,
Coxiella (C.) burnetii, and Chlamydophila species. Anti-
gen testing of S. pneumoniae and L. pneumophila was per-
formed in urine samples. Furthermore, pharyngeal swabs
were taken for viral culture and viral PCR. Finally, patients
were analysed for a serotype specific rise in S. pneumoniae
antibodies when two blood samples (one drawn at admis-
sion and one after discharge) were available. Antibodies
against pneumococcal polysaccharides were measured on
a Luminex platform (Luminex Corporation, Austin, TX),
using a quantitative multiplex immunoassay: the xMAP
pneumococcal immunity panel. More detailed information
can be found elsewhere [17].
If both a bacterium and virus were detected in a pa-
tient, the bacterial species was classified as the causative
pathogen. If two different bacterial species were identified,
the pathogen known to most likely cause CAP was consid-
ered causative. For the purpose of this study, aetiological
agents were classified into ten groups: the first seven
groups consist of the most frequently identified bacteria
(S. pneumoniae, C. burnetii, Haemophilus (H.) influenzae,
L. pneumophila, Chlamydophila species, M. pneumoniae,
and Staphylococcus aureus), group eight contains remaining
bacteria (‘Other pathogen’), group nine comprises viruses
(‘Viral pathogen’), and the last group consists of CAPs with
unidentified aetiology (‘No pathogen identified’).
Clinical outcomes
ICU admission during hospitalisation, length of stay,
in-hospital mortality, 30-day and one-year mortality
were documented for each patient.
Resource utilization and cost calculation
Hospital administrative databases were extracted for all
resource utilisation on a patient level. Resource items were
grouped in seven categories: general ward nursing, nursing
on ICU, clinical chemistry laboratory tests, microbiology
exams, radiology exams, medication drugs, and other.
Except for nursing, only resources plausibly related to
pneumonia treatment were selected. For example, medica-
tion drug use only included antibiotics, analgesics, bron-
chodilators, sedatives, blood products and antithrombotic
drugs. The category “other” comprised physical therapy
sessions, electro and echocardiograms, bronchoscopy and
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laryngoscopy and invasive empyema diagnostic and treat-
ment procedures. For duration of nursing, the unit of
measurement was number of days.
Total costs per patient were calculated by summing
the number of resources multiplied by the costs per
item. Costs per resource item were based on the National
Diagnosis Treatment Combination rates valued in 2011 or
2012 [18], except for nursing costs during hospital stay
and costs of medication drugs. Nursing costs for general
ward and ICU stay were based on mean costs per hospital
unit prices belonging to diagnostic treatment combination
code 401 (‘pneumonia’) for the year 2011. Costs of drugs
were based on the lowest medication drug price according
to the College for Health Insurance website valued in
2012 [19]; if not available on this website, the hospital’s
purchase price was recorded.
Data analyses
Overall, descriptives were stated as number (%), mean
(standard deviation (SD)) or median (interquartile range
(IQR)), and compared using independent samples T-test,
Chi-square test, or Mann–Whitney U test, where ap-
propriate. Kruskall Wallis test was used to assess overall
differences in length of stay and costs between aetiologic
groups.
To identify variables predicting costs of hospitalisation
for CAP, linear regression analyses were conducted with
log-transformed data. Costs were log-transformed to
correct for skewness of the data. First, the following
variables were examined in a univariate model (with
reference group): male gender (female), chronic obstruct-
ive pulmonary disease (no chronic obstructive pulmonary
disease), congestive heart failure (no congestive heart
failure), diabetes mellitus (no diabetes mellitus), PSI
classes IV-V (classes I-III), and admission in ‘Gelderse
Vallei Hospital’ (St. Antonius Hospital). The ten aetiologic
groups were included separately in the model; reference
value per group was composed of the other nine aetiologic
groups. Subsequently, variables significant in univariate
models (p < 0.10) were inserted in a multivariate model,
applying a backwards elimination technique retaining var-
iables with a p-value < 0.10. For the final model, effects
(costs) were stated as beta with corresponding standard
error for each independent variable. Data were analysed
with SPSS statistical software for Windows, version 21.0.
For all analyses, a p-value of <0.05 was considered statisti-
cally significant.
Results
A total of 505 patients with CAP were subject in this
study, with a mean age of 63.4 ± 18.0 years and a male/
female ratio of 1.4/1. Patient characteristics are presented
in Table 1.




Age in years (SD) 63.4 (18.0)
Male sex (%) 295 (58.4)
Comorbidities (%)
Chronic obstructive pulmonary disease 98 (19.4)
Congestive heart failure 68 (13.5)
Renal disease 40 (7.9)
Diabetes mellitus 77 (15.2)
Liver disease 2 (0.4)
Pneumonia Severity Index class I-III (%) 279 (55.2)
Pneumonia Severity Index class IV-V (%) 226 (44.8)
Pathogens (%)
Streptococcus pneumoniae 124 (24.6)
Coxiella burnetii 28 (5.5)
Haemophilus influenzae 27 (5.3)
Legionella pneumophila 20 (4.0)
Chlamydophila species 16 (3.2)
Mycoplasma pneumoniae 9 (1.8)
Staphylococcus aureus 9 (1.8)
Only viral pathogen 35 (6.9)
Other pathogen 27 (5.3)
No pathogen identified 210 (41.6)
Empirical antibiotic treatment (%)
Beta-lactam, penicillins (monotherapy) 254 (50.3)
Other beta-lactam (monotherapy) 86 (17.0)
Beta-lactam, penicillins + quinolone 34 (6.7)
Beta-lactam, penicillins + macrolides 33 (6.5)
Other beta-lactam + aminoglycoside 20 (4.0)
Other beta-lactam + quinolone 16 (3.2)
Quinolone (monotherapy) 11 (2.2)
Macrolides, lincosamides and streptogramins (monotherapy) 11 (2.2)
Beta-lactam, penicillin + aminoglycoside 7 (1.4)
Other beta-lactam, penicillin + macrolides 7 (1.4)
Sulfanomides and trimethoprim (monotherapy) 6 (1.2)
Tetracyclines (monotherapy) 6 (1.2)
Other 14 (2.8)
Outcomes
Length of hospital stay (IQR) 8.5 (6.0-13.0)
Intensive care unit admission (%) 38 (7.5)
In-hospital mortality (%) 24 (4.8)
30-Day mortality (%) 26 (5.1)
One-year mortality (%) 73 (14.5) ⊥
Data are presented as number (%), mean (SD) or median (IQR).
Abbreviations: IQR interquartile range, SD standard deviation.
⊥7 patients were lost to follow-up.
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Aetiology and clinical outcomes
In 294/505 (58.2%) patients, a causative pathogen was
identified. Table 2 lists the microbiological test results of
most frequently identified pathogens. Overall, S. pneumo-
niae was most prevalent (124/505, 24.6%). In 51 of these
124 patients, S. pneumoniae serotyping could be performed.
Type 1 was the most common serotype. A complete over-
view of the pneumococcal serotypes is given in Additional
file 1: Table S1. In 43/505 patients a mixed infection was
found. No penicillin resistant S. pneumoniae, methycillin-
resistant Staphylococcus aureus or multi-resistant gram-
negative pathogens were identified.
Clinical outcomes categorized by aetiology group are
listed in Table 3. Overall, LOS differed significantly be-
tween the major aetiological groups (p < 0.001). CAP
caused by either M. pneumoniae or C. burnetii was associ-
ated with a significantly shorter LOS compared to the other
aetiologic groups (p:0.007 and p < 0.001, respectively), while
S. pneumoniae CAPs resulted in a significantly longer
duration of hospital stay (p:0.03).
Hospital costs
For 361/505 (71.5%) of the patients complete resource
utilization data were available for analysis. The clinical
characteristics of the 144 patients who could not be in-
cluded, as compared to the included patients can be found
in Additional file 1: Table S2.
Total costs
Table 4 lists the top 10 most frequent and the top 10
most expensive resource items. In the Additional file 1,
the top 5 most frequent used items for each individual
category can be found in Table S3.
Figure 1 shows the total distribution of hospital costs
per patient. Total median hospital costs per patient were
€3,899 (IQR 2,911-5,684) with minimum costs of €901
and maximum costs of €112,634. Figure 2 shows the share
per category in the total costs: general ward nursing repre-
sented the largest share (56.5%), followed by nursing on
ICU (16.4%) and diagnostic microbiology exams (9.4%).
Table 2 Microbiology tests results of 505 patients hospitalised with community-acquired pneumonia
Sputum culture Sputum PCR Blood culture Blood PCR Urinary antigen test Serology
S. pneumoniae n = 124 46 - 42 - 78 1
Haemophilus influenzae n = 27 25 1 - - - 1
Legionella pneumophila n = 20 1 3 - - 15 6
Mycoplasma pneumoniae n = 9 - 4 - - - 7
Coxiella burnetii n = 28 1 12 2 12 - 20
Chlamydophila spp. n = 16 - 8 - - - 12
Staphylococcus aureus n = 9 8 - 1 - - -
Other pathogen n = 27 23 - 5 - - -
Viral pathogen n = 35 3 2 - - - 19
Abbreviations: n number, S. pneumoniae Streptococcus pneumoniae, spp species.











Streptococcus pneumoniae (n = 124) 8.5 (6.5-14.9) 10 (8.1) 4 (3.2) 4 (3.2) 12 (9.7)
Coxiella burnetii (n = 28) 5.5 (3.5-7.5) 0 0 1 (3.6) 1 (3.6)
Haemophilus Influenzae (n = 27) 9.0 (7.5-14.0) 2 (7.4) 0 0 3 (11.1)
Legionella pneumophila (n = 20) 11.0 (6.5-17.0) 3 (15.0) 1 (5.0) 1 (5.0) 2 (10.0)
Chlamydophila species (n = 16) 8.5 (6.6-13.3) 2 (12.5) 0 0 1 (6.3)
Mycoplasma pneumoniae (n = 9) 5.0 (4.5-7.3) 0 0 0 0
Staphylococcus aureus (n = 9) 10.5 (7.3-14.5) 1 (11.1) 3 (33.3) 3 (33.3) 4 (44.4)
Other pathogen (n = 27) 8.0 (5.0-15.8) 7 (25.9) 2 (7.4) 2 (7.4) 9 (33.3)
Viral pathogen (n = 35) 8.5 (6.3-13.5) 1 (2.9) 2 (5.7) 3 (8.6) 6 (17.1)
No pathogen found (n = 210) 8.5 (5.5-12.6) 12 (5.7) 12 (5.7) 12 (5.7) 35 (16.7)
Data are presented as number (%) or median (IQR). For calculation of median length of stay patients who died during admission where excluded from
the analysis.
Abbreviations: ICU intensive care unit, IQR interquartile range, n number.
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Costs categorized per aetiological group
Overall, total hospital costs differed between the 10
aetiological groups (p:0.002); costs for hospitalisation
of CAP caused by C. burnetii were significantly lower
(p < 0.001), while hospitalisation of patients with S.
pneumoniae as causative agent represents significantly
higher costs (p:0.03) compared to other aetiologies. For M.
pneumoniae and Staphylococcus aureus a trend towards
respectively lower and higher costs (p: 0.10 and p:0.08,
respectively) was observed.
Figure 3 shows median costs of each aetiologic group
subdivided into the seven resource categories. Raw
numbers of this figure can be found in Additional file 1:
Table S4. Overall, costs for general ward nursing, microbiol-
ogy exams, clinical chemistry laboratory tests, medication
drugs, and radiologic exams all differed between the
aetiological groups. On an individual pathogen level,
CAP caused by C. burnetii was lower in costs for nursing,
clinical chemistry tests, and radiological examinations
compared to most of the other aetiological groups. Costs
of medication were specifically high in patients with L.
pneumophila pneumonia. CAP caused by Staphylococcus
aureus was higher in costs for nursing and CAP caused
by S. pneumoniae was more expensive in radiological
Table 4 Top 10 most frequent and top 10 most expensive





10 Most frequent resource
items
1 Tissue obtainment (microbiology
and clinical chemistry)
18.1 13.73
2 Antibodies against any pathogen




3 General ward nursing (one day) 9.4 375.00
4 Sodium 8.2 1.76
5 Potassium 8.2 1.76
6 Creatinine 6.6 1.76
7 Glucose 6.4 1.76
8 Leukocytes 6.1 1.76
9 C-reactive protein 6.0 4.84
10 Urea 5.9 1.76
10 Most expensive resource
items
1 Intensive care unit nursing
(one day)
0.6 1,730.00
2 Surgical treatment of thorax
empyema
0.2 1,084.75




5 General ward nursing (one day) 9.4 375.00




8 Computer tomography of thorax 0.2 195.83
9 Immunopathologic research <0.1 109.57
10 Computer tomography airways <0.1 160.01
Figure 1 Distribution of total hospital costs in 361 patients
hospitalised with community-acquired pneumonia.
Figure 2 Distribution of costs of 361 patients hospitalised
with community-acquired pneumonia expressed by their
seven major resource categories. Legend: Abbreviations:
D, drugs; ICU, intensive care unit nursing; O, other; R,
radiology exams.
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examinations. Additional file 1: Table S5A to S5G shows
details of this aetiological subgroup analysis.
Costs per S. pneumoniae serotype
As S. pneumoniae is the most frequent identified pathogen
in CAP, costs of serotypes were explored grouped per
pneumococcal vaccine available in the European Union
(results presented in Additional file 1: Table S6). Total
costs of hospitalisation were not higher for patients with
CAP caused by the serotypes present in the different
vaccines compared to patients infected by pneumococcal
serotypes not included in these vaccines.
Identification of cost driving factors
To identify cost driving factors, a multivariable linear
regression model was constructed. Table 5 lists the var-
iables included in the final model together with their
corresponding regression coefficients. Staphylococcus
aureus, high PSI score (classes IV and V), and Strepto-
coccus pneumoniae were all independent cost driving
factors, increasing total costs of hospitalisation by 98%,
43%, and 18% respectively. Coxiella burnetii decreased
total costs of hospitalisation by 35%.
Discussion
In the past years, many studies have been conducted
aiming at finding new strategies to lower incidence and
improve clinical outcomes of CAP. To determine cost-
effectiveness of these strategies, knowledge about causing
microorganisms, clinical outcomes, and related costs is
needed. To our knowledge, this is the first study that
studies the potential associations between costs of hos-
pitalisation for CAP and its microbial aetiology. The
main finding in the present study is that costs related to
hospitalisation for CAP show great variation between pa-
tients, and CAP caused by S. pneumoniae and Staphylococ-
cus aureus is associated with significantly higher costs,
mainly due to longer duration of hospital stay.
In this study, S. pneumoniae was confirmed as the most
prevalent causative pathogen in CAP (24.6%). Compared
to other aetiological groups, median LOS (8.5 days), rate
of ICU admission (8%), and one-year mortality (9.7%) were
relatively higher for pneumonia caused by S. pneumoniae,
despite the relative younger age of patients of this
aetiological group (60.4 ± 19.0 years versus 64.4 ± 17.6 years,
p:0.033). These findings are in accordance with other CAP
studies that also reported higher disease severity and
Figure 3 Median hospital costs in euro with interquartile range per aetiology differentiated by resource group. Legend: Abbreviations: C.
burnetii, Coxiella burnetii; H. influenzae, Haemophilus influenzae; ICU, intensive care unit; L. pneumophila, Legionella pneumophila; M. pneumoniae,
Mycoplasma pneumoniae; n, number; spp, species; S. pneumoniae, Streptococcus pneumoniae.
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increased need for ICU admission in S. pneumoniae
pneumonia [20,21]. In agreement with these findings,
we showed S. pneumoniae to be an independent cost-
driving factor (on average plus 18% per hospitalisation).
Interestingly, Staphylococcus aureus could also be
identified as an independent cost driving factor. CAPs
caused by this pathogen were associated with a longer
LOS and a higher mortality rate as well. This unfavour-
able outcome might be explained by the difficulty of
treating Staphylococcus aureus pulmonary and systemic
infections. Recently, Restrepo et al. have reported that
late ICU admission versus early ICU admission is more
prevalent in cases of CAP caused by Staphylococcus
aureus, which aligns with the higher mortality rate ob-
served in our study [22].
In our study, median total costs of hospitalisation were
almost €4,000 per patient. These expenditures are higher
compared to similar studies performed in Germany and
Spain (median costs of €1,362 [23], €1,683 [24] and
€1,553 [25], respectively), but lower than reported in a
study from the United Kingdom (£1,700-5,100, depending
on length of stay [7]) and a European study (US$6,530 in a
secondary-level hospital in the Netherlands and US$8,444
in a teaching hospital) [26]. The most likely explanation for
these discrepancies in hospital costs are expected to be
differences in registration, and individual resource item
prices. Furthermore, diagnostic and treatment standards
might differ between countries, leading to other price cal-
culations. The recent study of Ostermann et al., however,
showed no large differences in mean total duration of hos-
pital stay for CAP between several EU countries (range
9.6-15.0 days) [26]. Unfortunately, most published studies
do not indicate prices of individual resource items, which
makes detailed comparisons between studies very difficult.
Besides this, none of the available studies in literature
included aetiological groups in their analyses, further
limiting the possibility of a relative comparison with our
study findings at this moment.
A further relevant finding in our study was that 57%
of the total costs of hospitalisation is due to general
ward nursing. This finding is in accordance with other
costs studies [27,28]. The latter is also reflected by C.
burnetii, causing a relatively milder course of the disease
and a significant shorter duration of hospital stay, being
identified as an independent cost limiting factor in the
multivariable model.
In the present study, costs of medication represented a
very small part of the total costs of hospitalisation (on
Table 5 Multivariable linear regression model to predict total costs of hospitalisation in 361 patients with
community-acquired pneumonia
Crude analysis Multivariable analysis
Independent variables B SE p-value B SE p-value
CONSTANT 3.558 0.023 <0.001
Male gender 0.009 0.032 0.77
Chronic obstructive pulmonary disease 0.009 0.044 0.83
Congestive heart failure 0.083 0.045 0.06
Chronic renal disease 0.077 0.057 0.17
Diabetes mellitus 0.047 0.045 0.30
Pneumonia Severity Index classes IV-V 0.176 0.030 <0.001 0.158 0.030 <0.001
Hospital ‘Gelderse Vallei’ −0.063 0.042 0.13
Pathogens:
Streptococcus pneumoniae 0.070 0.038 0.07 0.067 0.036 0.07
Coxiella burnetii −0.198 0.058 0.001 −0.129 0.056 0.02
Haemophilus influenzae −0.047 0.087 0.59
Legionella pneumophila 0.060 0.076 0.43
Chlamydophila species 0.087 0.076 0.25
Mycoplasma pneumoniae −0.179 0.134 0.18
Staphylococcus aureus 0.358 0.148 0.02 0.362 0.140 0.01
Viral pathogen −0.046 0.064 0.48
Other pathogen 0.163 0.073 0.03 0.131 0.070 0.06
No pathogen found −0.034 0.031 0.28
Prices are log-transformed and stated in euro.
Abbreviations: B beta coefficient, SE standard error.
Bold numbers are included in the final model (p < 0.10).
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average 3.2%). This means that policies aiming at an early
intravenous to oral switch of antimicrobial treatment will
not result in substantial cost-savings by reducing drug-
expenses; costs might be reduced if the switch resulted in
earlier hospital discharge. Medication costs for pneumonia
caused by Legionella pneumophila appeared significantly
higher compared to other aetiological groups. This is most
likely caused by a higher ICU admission rate for these
pneumonias and linked to the use of specific drugs such
as fresh frozen plasma and sedatives.
This study has several strengths. First, we were able to
identify the causative pathogen in a large number of pa-
tients enabling comparisons between aetiological groups.
Second, we analysed resource utilization on an individual
patient level. Third, data of two hospitals were studied
(showing no differences) adding to the external validity
of the findings. Besides this, the characteristics of the
patients studied resemble data from another large nation-
wide CAP cohort from the Netherlands further adding to
the generalisability of the findings [15].
There are also limitations that need to be addressed.
First, due to missing data in some resources categories,
not all 505 patients could be included in the overall cost
analyses. This was due to being unable to retrieve some
resource use from the years 2004 until 2006. We con-
sider, however, that this has no impact on the validity
of the findings because the more recent years are fully
included , making the total costs of hospitalisation rep-
resentative for the present standard of care for CAP. A
further reassuring factor is that the comparison of pa-
tient characteristics and clinical outcomes of the 361
patients included in the analyses with the 144 patients
not included, showed no large differences (see Additional
file 1: Table S2). However, the lower number of patients
available for analysis resulted in some aetiological sub-
groups becoming rather small.
Another limitation is that patients directly admitted to
the ICU were absent in the study cohorts used. In the
most recent cohort, 25 of the 817 eligible patients (3%)
were not included due to direct ICU admission. This
phenomenon could have lead to an underestimation of
the absolute costs of hospitalisation for CAP. However,
given this low percentage, we expect this effect to be rather
small. Furthermore, it is very unlikely to have biased the
relative costs per pathogen.
Finally, we cannot rule out that the costs related to
microbiology exams are overestimated (9% share of
total costs of hospitalisation). We studied patients who
had participated in clinical studies in which a large
panel of microbiological tests had been performed to
maximize pathogen identification. However, presuming
this resulted in a 50% increase in microbiology costs,
decreasing these costs by 50% influences the total costs
by less than 5%. In the present study, 58.2% of the
causative pathogens could be identified, which is relatively
high as compared to other studies [9].
Conclusions
In conclusion, in the present study we have shown that
the total costs of hospitalisation for CAP vary considerably
between patients and this variation can be largely ex-
plained by differences in length of hospital stay. Increased
disease severity, and S. pneumoniae and Staphylococcus
aureus as causative pathogens, are independent cost
driving factors. This suggests, from a cost perspective,
to focus further research on better in-hospital treatment
and prevention of CAP caused by these pathogens. As
standards of care and individual resource item prices are
expected to differ between countries, further study in other
countries should be performed to confirm the results of this
study.
Consent
From all patients written informed consent was obtained
in both studies.
Additional file
Additional file 1: Web appendix: Table S1. Serotype distribution in 51
patients with Streptococcus pneumoniae pneumonia. Table S2. Patient
characteristics of 361 patients included in the pneumonia cost analyses
compared to patients not included in the cost analyses. Table S3. Top 5
most frequently used items for each resource group. Table S4. Median
hospital costs in euro with interquartile range per aetiology differentiated by
resource group. Table S5. P-values of the seven resource categories subdivided
by ten aetiologic groups. Table S6. Median total costs of hospitalisation in
euro of pneumococcal vaccines serotypes compared with costs of
non-vaccine serotypes, with serotyping determined in two manners.
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